In 2023, two vaccines were approved for use in Canada for the prevention of lower respiratory tract infections caused by respiratory syncytial virus (RSV) in people aged 60 years and older; however, their uptake may be hindered by vaccine fatigue, hesitancy, and persisting misconceptions that RSV is largely a concern among children. While hospitalization rates due to RSV are highest among children under the age of 1 year, mortality rates are highest among older adults. Reaching this population with safe and effective vaccines will save lives.

Read More